Research Center on Neglected Diseases, Guarulhos University, São Paulo, Brazil.
Department of Infectious and Parasitic Diseases, Faculty of Medicine, Laboratory of Immunopathology of Schistosomiasis (LIM-06), University of São Paulo, São Paulo, Brazil.
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0011424. doi: 10.1128/aac.00114-24. Epub 2024 May 23.
Schistosomiasis, a widespread parasitic disease caused by the blood fluke of the genus , affects over 230 million people, primarily in developing countries. Praziquantel, the sole drug currently approved for schistosomiasis treatment, demonstrates effectiveness against patent infections. A recent study highlighted the antiparasitic properties of amiodarone, an anti-arrhythmic drug, exhibiting higher efficacy than praziquantel against prepatent infections. This study assessed the efficacy of amiodarone and praziquantel, both individually and in combination, against through comprehensive and experiments. experiments demonstrated synergistic activity (fractional inhibitory concentration index ≤0.5) for combinations of amiodarone with praziquantel. In a murine model of schistosomiasis featuring prepatent infections, treatments involving amiodarone (200 or 400 mg/kg) followed by praziquantel (200 or 400 mg/kg) yielded a substantial reduction in worm burden (60%-70%). Given the low efficacy of praziquantel in prepatent infections, combinations of amiodarone with praziquantel may offer clinical utility in the treatment of schistosomiasis.
血吸虫病是一种由血吸虫属的血吸引起的广泛流行的寄生虫病，影响了超过 2.3 亿人，主要在发展中国家。目前唯一被批准用于治疗血吸虫病的药物是吡喹酮，它对现症感染有效。最近的一项研究强调了抗心律失常药物胺碘酮的抗寄生虫特性，它对未现症感染的疗效高于吡喹酮。这项研究通过全面的体内和体外实验评估了胺碘酮和吡喹酮单独和联合使用对血吸虫的疗效。体内实验表明，胺碘酮与吡喹酮联合使用具有协同活性（分数抑制浓度指数≤0.5）。在一个具有未现症感染的血吸虫病小鼠模型中，用胺碘酮（200 或 400mg/kg）治疗后再用吡喹酮（200 或 400mg/kg）治疗，可使虫体负荷量减少 60%-70%。鉴于吡喹酮在未现症感染中的疗效较低，胺碘酮与吡喹酮联合使用可能在血吸虫病治疗中具有临床应用价值。
